MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit .

Investor Contact

Tina Ventura, 

Media Contact

Christopher Frates, 



EN
18/10/2024

Underlying

MDGLMadrigal Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Madrigal Pharmaceuticals

Free Trial
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Inc: 1 director

A director at Madrigal Pharmaceuticals Inc sold 3,400 shares at 350.302USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

MDGL MADRIGAL PHARMACEUTICALS
7h / 52m 7h / 52m 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcomi...

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wednesday, November 13, 2024 at 2:00 P.M. ESTThe presentation will be webcast live and may be accessed . 7th Annual Evercore HealthCONx ConferenceWednesday, December 4, 2024 at 9:35 A.M. EST Piper Sandler 36th Annual Healthcare ConferenceThursday, ...

November 6, 2024 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results ...

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosisReports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024Company to host conference call today, October 31, 2024, at...

October 31, 2024 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) A...

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego. Bill Si...

October 30, 2024 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Stu...

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomesStudy may also support full approval of RezdiffraTM (resmetirom) in noncirrhotic NASH CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delive...

October 21, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch